A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Malaria during pregnancy, particularly Plasmodium falciparum malaria, has been linked to increased morbidity and mortality, which must be reduced by both preventive measures and effective case management. The World Health Organization (WHO) recommends artemisinin-based combination therapy (ACT) to treat uncomplicated falciparum malaria during the second and third trimesters of pregnancy, and quinine plus clindamycin during the first trimester. However, the national policies of many African countries currently recommend quinine throughout pregnancy. Therefore, the aim of this article is to provide a summary of the available data on the safety and efficacy of artemether-lumefantrine (AL) in pregnancy. An English-language search identified 16 publications from 1989 to October 2011 with reports of artemether or AL exposure in pregnancy, including randomized clinical trials, observational studies and systematic reviews. Overall, there were 1,103 reports of AL use in pregnant women: 890 second/third trimester exposures; 212 first trimester exposures; and one case where the trimester of exposure was not reported. In the second and third trimesters, AL was not associated with increased adverse pregnancy outcomes as compared with quinine or sulphadoxine-pyrimethamine, showed improved tolerability relative to quinine, and its efficacy was non-inferior to quinine. There is evidence to suggest that the pharmacokinetics of anti-malarial drugs may change in pregnancy, although the impact on efficacy and safety needs to be studied further, especially since the majority of studies report high cure rates and adequate tolerability. As there are fewer reports of AL safety in the first trimester, additional data are required to assess the potential to use AL in the first trimester. Though the available safety and efficacy data support the use of AL in the second and third trimesters, there is still a need for further information. These findings reinforce the WHO recommendation to treat uncomplicated falciparum malaria with quinine plus clindamycin in early pregnancy and ACT in later pregnancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Artemether-lumefantrine (AL, Coartem) is effective and safe in the treatment of malaria during pregnancy [196].”
From Current update on malaria in pregnancy: a systematic review (2025) · cites this paper as [196]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weltgesundheitsorganisation (2005) · Cited by 3,799
Epidemiology and burden of malaria in pregnancy
Desai, M., ter Kuile, F. O., Nosten, F., McGready, R., Asamoa, K., Brabin, B., & Newman, R. D. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70021-x · Cited by 1,432 · cited 1×
“Malaria during pregnancy is associated with an increased risk of maternal anaemia, maternal death, abortion, premature labour, low birth weight, and neonatal death [1,7,38].”
BackgroundQuantifying the Number of Pregnancies at Risk of Malaria in 2007: A Demographic Study
Dellicour, S., Tatem, A. J., Guerra, C. A., Snow, R. W., & ter Kuile, F. O. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000221 · Cited by 490 · cited 1×
“4 million pregnancies occurred in areas of unstable transmission [4].”
BackgroundTER KUILE, F. O., PARISE, M. E., VERHOEFF, F. H., UDHAYAKUMAR, V., NEWMAN, R. D., VAN EIJK, A. M., ROGERSON, S. J., & STEKETEE, R. W. (2004) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2004.71.41 · Cited by 364
Pharmacokinetics and Pharmacodynamics of Lumefantrine (Benflumetol) in Acute Falciparum Malaria
Ezzet, F., van Vugt, M., Nosten, F., Looareesuwan, S., & White, N. J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.697-704.2000 · Cited by 354 · cited 3×
“Small changes in AL exposure during pregnancy have been reported [21,25], but these results should be viewed with caution as they involve inter-trial comparisons, small populations, high inter-individual variation in plasma levels and the average plasma levels reported are comparable with data from non-pregnant adults…”
BackgroundResultWHO Guidelines for the treatment of malaria
Kunte, R., & Kunwar, R. (2011) · Medical Journal Armed Forces India · doi:10.1016/s0377-1237(16)30022-3 · Cited by 341
Artemisinin-based combination therapy for treating uncomplicated malaria
Sinclair, D., Zani, B., Donegan, S., Olliaro, P., & Garner, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007483.pub2 · Cited by 286
McGready, R., Lee, S., Wiladphaingern, J., Ashley, E., Rijken, M., Boel, M., Simpson, J., Paw, M., Pimanpanarak, M., Mu, O., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70339-5 · Cited by 228 · cited 2×
“…[21], Dellicour et al., 2007 [14], McGready et al., 2008 [22], Kaye et al., 2008 [23], Orton et al., 2008 [61], Adam et al., 2009 [24], Tarning et al., 2009 [37], Piola et al., 2010 [25], Manyando et al., 2010 [26], McGready et al., 2011 [29], Sangaré et al., 2011 [27], Wilby and Ensom, 2011 [30].”
ResultPiola, P., Fogg, C., Bajunirwe, F., Biraro, S., Grandesso, F., Ruzagira, E., Babigumira, J., Kigozi, I., Kiguli, J., Kyomuhendo, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66416-1 · Cited by 211
Lefèvre, G., Looareesuwan, S., Treeprasertsuk, S., Krudsood, S., Silachamroon, U., Gathmann, I., Mull, R., & Bakshi, R. (2001) · The American journal of tropical medicine and hygiene · doi:10.4269/ajtmh.2001.64.247 · Cited by 178 · cited 2×
“Small changes in AL exposure during pregnancy have been reported [21,25], but these results should be viewed with caution as they involve inter-trial comparisons, small populations, high inter-individual variation in plasma levels and the average plasma levels reported are comparable with data from non-pregnant adults…”
MethodResultMcGready, R., Cho, T., Keo, N. K., Thwai, K. L., Villegas, L., Looareesuwan, S., White, N. J., & Nosten, F. (2001) · Clinical Infectious Diseases · doi:10.1086/324349 · Cited by 178 · cited 9×
“In the Thai study, 11 pregnant women with acute falciparum malaria received artemether, either alone or combined with mefloquine, artesunate, clindamycin, or lumefantrine between 1992 and 2000 [17].”
BackgroundInfluentialTHE CONTRIBUTION OF MALARIA IN PREGNANCY TO PERINATAL MORTALITY
VAN GEERTRUYDEN, J.-P., THOMAS, F., ERHART, A., & D’ALESSANDRO, U. (2004) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2004.71.35 · Cited by 161
Self-citationAn Autopsy Study of Maternal Mortality in Mozambique: The Contribution of Infectious Diseases
Menéndez, C., Romagosa, C., Ismail, M. R., Carrilho, C., Saute, F., Osman, N., Machungo, F., Bardaji, A., Quintó, L., Mayor, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050044 · Cited by 150 · cited 1×
“Although all Plasmodium species can affect maternal and foetal health, Plasmodium falciparum infection is associated with the most severe effects and has been linked to increased maternal, foetal and neonatal morbidity and mortality [1-3].”
BackgroundUnderstanding the pharmacokinetics of Coartem®
DJIMDÉ, A. A., & Lefèvre, G. Y. (2009) · Malaria Journal · doi:10.1186/1475-2875-8-s1-s4 · Cited by 148 · cited 1×
“Small changes in AL exposure during pregnancy have been reported [21,25], but these results should be viewed with caution as they involve inter-trial comparisons, small populations, high inter-individual variation in plasma levels and the average plasma levels reported are comparable with data from non-pregnant adults…”
ResultMcGready, R., Tan, S. O., Ashley, E. A., Pimanpanarak, M., Viladpai-nguen, J., Phaiphun, L., Wüstefeld, K., Barends, M., Laochan, N., Keereecharoen, L., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050253 · Cited by 136
Impact of Malaria at the End of Pregnancy on Infant Mortality and Morbidity
Bardají, A., Sigauque, B., Sanz, S., Maixenchs, M., Ordi, J., Aponte, J. J., Mabunda, S., Alonso, P. L., & Menéndez, C. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq049 · Cited by 136 · cited 1×
“In a large study of 1,030 pregnant women in Mozambique, acute placental infection and parasitaemia in cord blood were significantly associated with infant death, while maternal clinical falciparum malaria and acute placental infection were associated with clinical malaria during infancy [8].”
BackgroundMcGready, R., Stepniewska, K., Lindegardh, N., Ashley, E. A., La, Y., Singhasivanon, P., White, N. J., & Nosten, F. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0199-7 · Cited by 115
The clinical efficacy of artemether/lumefantrine (Coartem®)
Makanga, M., & Krudsood, S. (2009) · Malaria Journal · doi:10.1186/1475-2875-8-s1-s5 · Cited by 109 · cited 1×
“The efficacy of AL during pregnancy in the two Ugandan trials, but not the Thai trial, is similar to the results from studies in adults and children that have consistently reported AL efficacy of over 95% [44].”
ResultCase management of malaria in pregnancy
Nosten, F. H., McGready, R. M., & Mutabingwa, T. K. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70023-3 · Cited by 103 · cited 2×
“Nevertheless, malaria infection is associated with severe maternal anaemia, placental malaria and low birth weight – a risk factor for infant death [6,7].”
BackgroundAshley, E. A., Stepniewska, K., Lindegårdh, N., McGready, R., Annerberg, A., Hutagalung, R., Singtoroj, T., Hla, G., Brockman, A., Proux, S., et al. (2007) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2006.01785.x · Cited by 101 · cited 5×
“34 μg/ml reported in pregnant women in this study was well within the range of values reported in non-pregnant female and male patients in several other studies [31-33].”
BackgroundMethodResultInfluentialArtemisinin derivatives in the treatment of falciparum malaria in pregnancy
McGready, R., Cho, T., Cho, J. J., Simpson, J. A., Luxemburger, C., Dubowitz, L., Looareesuwan, S., White, N. J., & Nosten, F. (1998) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(98)91081-1 · Cited by 101 · cited 2×
“To avoid duplication of pregnancy exposures, the other two reports have not been included [18,19].”
BackgroundMethodPiola, P., Nabasumba, C., Turyakira, E., Dhorda, M., Lindegardh, N., Nyehangane, D., Snounou, G., Ashley, E. A., McGready, R., Nosten, F., et al. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70202-4 · Cited by 99 · cited 11×
“2% (PCR-corrected at delivery (or Day 42 if later)), venous lumefantrine levels were assessed in 97 women [25].”
BackgroundMethodResultInfluentialTarning, J., McGready, R., Lindegardh, N., Ashley, E. A., Pimanpanarak, M., Kamanikom, B., Annerberg, A., Day, N. P. J., Stepniewska, K., Singhasivanon, P., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00195-09 · Cited by 99 · cited 8×
“, 2009 [37] Pharmacokinetic study of AL in pregnancy using capillary plasma samples (n = 103) Capillary plasma: 391 ng/ml (126–1,600), venous plasma (approx): 310 ng/ml (94–1,364) AUC0!∞, median (range): 472 μg/ml.”
BackgroundResultInfluentialThe safety of artemisinins during pregnancy: a pressing question
Dellicour, S., Hall, S., Chandramohan, D., & Greenwood, B. (2007) · Malaria Journal · doi:10.1186/1475-2875-6-15 · Cited by 92 · cited 3×
“[14], a total of 86 pregnancies were exposed to artemether across four studies: one in Nigeria, one in Sudan, one in Thailand, and one in China (Tables 1 and 2, Additional file 4).”
BackgroundGerman, P., Parikh, S., Lawrence, J., Dorsey, G., Rosenthal, P. J., Havlir, D. V., Charlebois, E. D., Hanpithakpong, W., Lindegårdh, N., & Aweeka, F. T. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181acb4ff · Cited by 91 · cited 1×
“This study showed a two- to three-fold increase in lumefantrine exposure (AUC) and small decreases in artemether and DHA exposure (AUC and Cmax) when AL and lopinavir/ritonavir were co-administered [51].”
BackgroundPharmacokinetic interaction trial between co-artemether and mefloquine
Lefèvre, G. Y., Bindschedler, M., Ezzet, F., Schaeffer, N., Meyer, I., & Thomsen, M. S. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00060-9 · Cited by 67 · cited 2×
“Small changes in AL exposure during pregnancy have been reported [21,25], but these results should be viewed with caution as they involve inter-trial comparisons, small populations, high inter-individual variation in plasma levels and the average plasma levels reported are comparable with data from non-pregnant adults…”
ResultManyando, C., Mkandawire, R., Puma, L., Sinkala, M., Mpabalwani, E., Njunju, E., Gomes, M., Ribeiro, I., Walter, V., Virtanen, M., et al. (2010) · Malaria Journal · doi:10.1186/1475-2875-9-249 · Cited by 67 · cited 12×
“AL, artemether-lumefantrine; AE, adverse events; SAE, serious adverse events; SP, sulphadoxine-pyrimethamine; ACT, artemisininbased combination therapies; National treatment policy is quinine throughout pregnancy [55-57]; National treatment policy is quinine in the first trimester and ACT in the second and third trime…”
BackgroundMethodResultInfluentialSelf-citationWhitty, C. J. M., Edmonds, S., & Mutabingwa, T. K. (2005) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2005.00714.x · Cited by 61
Clark, R. L., Lerman, S. A., Cox, E. M., Gristwood, W. E., & White, T. E. K. (2008) · Birth Defects Research Part B: Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20165 · Cited by 60 · cited 1×
“ACT is not recommended by the WHO as a first-line treatment during the first trimester, due to limited clinical safety data [11] and evidence of embryo lethality and developmental abnormalities in animal studies following artemisinin exposure early in pregnancy, at times equivalent to the first trimester in humans [12…”
BackgroundDrugs for treating uncomplicated malaria in pregnant women
Orton, L., & Omari, A. A. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004912.pub3 · Cited by 59
Birku, Y., Mekonnen, E., Björkman, A., & Wolday, D. (2002) · PubMed · Cited by 58
Sensitive periods for developmental toxicity of orally administered artesunate in the rat
White, T. E. K., & Clark, R. L. (2008) · Birth Defects Research Part B: Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20157 · Cited by 57 · cited 1×
“ACT is not recommended by the WHO as a first-line treatment during the first trimester, due to limited clinical safety data [11] and evidence of embryo lethality and developmental abnormalities in animal studies following artemisinin exposure early in pregnancy, at times equivalent to the first trimester in humans [12…”
BackgroundMcGready, R., White, N., & Nosten, F. (2011) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2010.02810.x · Cited by 54 · cited 3×
“It has been reported that the pharmacokinetics of antimalarial treatments may change during pregnancy [29,30].”
BackgroundChi, B. H., Vwalika, B., Killam, W. P., Wamalume, C., Giganti, M. J., Mbewe, R., Stringer, E. M., Chintu, N. T., Putta, N. B., Liu, K. C., et al. (2011) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2010.11.013 · Cited by 48 · cited 1×
“There have been calls for anti-malarial pregnancy exposure registries for large-scale data collection [42], and recently the design, feasibility and implementation of an Electronic Perinatal Record system was successfully tested in Lusaka, Zambia [43].”
BackgroundMorris, C. A., Onyamboko, M. A., Capparelli, E., Koch, M. A., Atibu, J., Lokomba, V., Douoguih, M., Hemingway-Foday, J., Wesche, D., Ryder, R. W., et al. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-114 · Cited by 48
Dellicour, S., ter Kuile, F. O., & Stergachis, A. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050187 · Cited by 45 · cited 1×
“There have been calls for anti-malarial pregnancy exposure registries for large-scale data collection [42], and recently the design, feasibility and implementation of an Electronic Perinatal Record system was successfully tested in Lusaka, Zambia [43].”
BackgroundInteraction Trial between Artemether‐Lumefantrine (Riamet®) and Quinine in Healthy Subjects
Lefèvre, G. Y., Carpenter, P., Souppart, C., Schmidli, H., Martin, J. M., Lane, A., Ward, C., & Amakye, D. D. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002237995 · Cited by 43 · cited 2×
“Small changes in AL exposure during pregnancy have been reported [21,25], but these results should be viewed with caution as they involve inter-trial comparisons, small populations, high inter-individual variation in plasma levels and the average plasma levels reported are comparable with data from non-pregnant adults…”
ResultArtemether in the treatment of falciparum malaria during pregnancy in eastern Sudan
Adam, I., Elwasila, E., Mohammed Ali, D. A., Elansari, E., & Elbashir, M. I. (2004) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/j.trstmh.2003.11.008 · Cited by 42 · cited 1×
“Wang, 1989 [20], Sowunmi et al., 1998 [15], McGready et al., 2001 [17], Adam et al., 2004 [16], McGready et al., 2006 [21], Dellicour et al., 2007 [14], McGready et al., 2008 [22], Kaye et al., 2008 [23], Orton et al., 2008 [61], Adam et al., 2009 [24], Tarning et al., 2009 [37], Piola et al., 2010…”
The Thai-Burmese border: drug studies of Plasmodium falciparum in pregnancy
McGready, R., & Nosten, F. (1999) · Annals of Tropical Medicine and Parasitology · doi:10.1080/00034989957709 · Cited by 41 · cited 2×
“To avoid duplication of pregnancy exposures, the other two reports have not been included [18,19].”
BackgroundMethodInteraction Trial between Artemether-Lumefantrine (Riamet®) and Quinine in Healthy Subjects
Lefèvre, G. Y., Carpenter, P., Souppart, C., Schmidli, H., Martin, J. M., Lane, A., Ward, C., & Amakye, D. D. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002401382632 · Cited by 41
Safety of artemisinins during early pregnancy, assessed in 62 Sudanese women
Adam, I., Elhassan, E. M., Omer, E. M., Abdulla, M. A., Mahgoub, H. M., & Adam, G. K. (2009) · Annals of Tropical Medicine & Parasitology · doi:10.1179/136485909x398285 · Cited by 40 · cited 4×
“Another recent observational study investigated the safety of artemisinins in the first trimester of pregnancy in Sudan between 2006 and 2008 [24].”
BackgroundInfluentialOnyamboko, M. A., Meshnick, S. R., Fleckenstein, L., Koch, M. A., Atibu, J., Lokomba, V., Douoguih, M., Hemingway-Foday, J., Wesche, D., Ryder, R. W., et al. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-49 · Cited by 37 · cited 1×
“These analyses, together with recent results suggesting that DHA clearance may be approximately 42% higher in pregnant women [46,47], support the view that further study of the pharmacokinetics of AL in pregnancy would be of benefit to help maintain confidence in dosing regimens and ensure that pregnant women receive…”
ResultSOWUNMI A. M. J. ODUOLA O. A. T. OG, A. (1998) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443619867038 · Cited by 36 · cited 4×
“All infants were normal at birth and showed normal physical and neurological development for the period of assessment, which varied between six and 36 months [15].”
BackgroundInfluentialClark, R. L. (2011) · Birth Defects Research Part A Clinical and Molecular Teratology · doi:10.1002/bdra.22868 · Cited by 35 · cited 1×
“Recent studies in animals and humans have suggested that the risk of embryotoxicity from artemisinins may be higher in pregnant women who do not have malaria than those with malaria, as healthy volunteers taking artemisinins have shown greater decreases in reticulocyte count, a possible marker for embryotoxicity, than…”
BackgroundGeertruyden, J. V. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s4483 · Cited by 32 · cited 1×
“There are several reports that HIV infection may influence the outcome of anti-malarial treatments, although the reported effects differ between the studies [49].”
ResultPatterns of anti-malarial drug treatment among pregnant women in Uganda
Sangaré, L. R., Weiss, N. S., Brentlinger, P. E., Richardson, B. A., Staedke, S. G., Kiwuwa, M. S., & Stergachis, A. S. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-152 · Cited by 32 · cited 1×
“…[21], Dellicour et al., 2007 [14], McGready et al., 2008 [22], Kaye et al., 2008 [23], Orton et al., 2008 [61], Adam et al., 2009 [24], Tarning et al., 2009 [37], Piola et al., 2010 [25], Manyando et al., 2010 [26], McGready et al., 2011 [29], Sangaré et al., 2011 [27], Wilby and Ensom, 2011 [30].”
Pharmacokinetics of Antimalarials in Pregnancy: A Systematic Review
Wilby, K. J., & Ensom, M. H. H. (2011) · Clinical Pharmacokinetics · doi:10.2165/11594550-000000000-00000 · Cited by 32
Wang, T. Y. (1989) · PubMed · Cited by 32
Kaye, D. K., Nshemerirwe, R., Mutyaba, T. S., & Ndeezi, G. (2008) · Journal of Infection in Developing Countries · doi:10.3855/t2.2.135 · Cited by 27
Kaye, D. K., Nshemerirwe, R., Mutyaba, T. S., & Ndeezi, G. (2008) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.285 · Cited by 25 · cited 1×
“…1998 [15], McGready et al., 2001 [17], Adam et al., 2004 [16], McGready et al., 2006 [21], Dellicour et al., 2007 [14], McGready et al., 2008 [22], Kaye et al., 2008 [23], Orton et al., 2008 [61], Adam et al., 2009 [24], Tarning et al., 2009 [37], Piola et al., 2010 [25], Manyando et al., 2010…”
Malaria in South Sudan 4: treatment of uncomplicated P. falciparum malaria.
Azairwe, R., & Achan, J. (2011) · South Sudan Medical Journal · doi:10.4314/ssmj.v4i2 · Cited by 11 · cited 2×
“AL, artemether-lumefantrine; AE, adverse events; SAE, serious adverse events; SP, sulphadoxine-pyrimethamine; ACT, artemisininbased combination therapies; National treatment policy is quinine throughout pregnancy [55-57]; National treatment policy is quinine in the first trimester and ACT in the second and third trime…”
Background
Research works printed but not linked: 2
- Poespoprodjo JR Fobia W Kenangalem E Lampah DA Sugiarto P Tjitra E Anstey NM Price RN Highly effective therapy for malaria in pregnancy improves maternal and neonatal health outcome [abstract] Am J Trop Med Hyg 2011 85 Suppl 6 Abstract number 455
- Ugandan Malaria Control Programme Ugandan National Policy on Malaria 2005 http://www.health.go.ug/mcp/NationalPolicyonMalariaTreatment(07_03_06).pdf
Cited by
UK malaria treatment guidelines 2016
Lalloo, D. G., Shingadia, D., Bell, D. J., Beeching, N. J., Whitty, C. J. M., & Chiodini, P. L. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.02.001 · Cited by 250
Kajubi, R., Ochieng, T., Kakuru, A., Jagannathan, P., Nakalembe, M., Ruel, T., Opira, B., Ochokoru, H., Ategeka, J., Nayebare, P., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32224-4 · Cited by 136
Four Artemisinin-Based Treatments in African Pregnant Women with Malaria
The PREGACT Study Group (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1508606 · Cited by 99
Lapinsky, S. E. (2013) · Critical Care Clinics · doi:10.1016/j.ccc.2013.03.006 · Cited by 88
“A World Health Organization report supported by a systematic review suggests treating first-trimester severe malaria with quinine plus clindamycin, and second-trimester and third-trimester disease with artemisinins.(44)”
BackgroundMinja, D. T. R., Schmiegelow, C., Mmbando, B., Boström, S., Oesterholt, M., Magistrado, P., Pehrson, C., John, D., Salanti, A., Luty, A. J. F., et al. (2013) · Emerging Infectious Diseases · doi:10.3201/eid1909.130133 · Cited by 81
Metadata
- Authors
- Manyando, C., Kayentao, K., D’Alessandro, U., Okafor, H. U., Juma, E., & Hamed, K.
- Affiliations
- Tropical Diseases Research Centre (ZM)
- Malaria Research and Training Center (ML)
- MRC Unit the Gambia (GM)
- University of Nigeria (NG)
- Kenya Medical Research Institute (KE)
- Corresponding author
- Manyando, Christine
- Venue
- Malaria Journal
- Published
- 2012-05-01
- Volume
- 11
- Issue
- 1
- Pages
- 141-141
- ISSN
- 1475-2875 (ISSN-L)
- PMC
- PMC3405476
- OpenAlex
- W2099127084
- Cited by
- 62
- References
- 51
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 3 · 2022: 2 · 2020: 2 · 2019: 1 · 2018: 4 · 2017: 7 · 2016: 11 · 2015: 9 · 2014: 10 · 2013: 7 · 2012: 1
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0 (tdm)
- Locations
- Malaria Journal (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Novartis Pharma
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Keywords
- artemether-lumefantrine, falciparum malaria, malaria in pregnancy, uncomplicated malaria, artemisinin-based combination therapy, drug safety in pregnancy, drug efficacy, sulfadoxine-pyrimethamine, first trimester exposure, pharmacokinetics in pregnancy, adverse pregnancy outcomes
- MeSH terms
- Artemether, Lumefantrine Drug Combination, Antimalarials, Drug Combinations, Ethanolamines, Female, Fluorenes, Humans, Pregnancy, Pregnancy Complications, Infectious, Pyrimethamine, Quinine, Sulfadoxine, Malaria, Falciparum, Treatment Outcome, Artemisinins, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.